Capital Research Global Investors Portfolio holdings
Capital Research Global Investors (CRGI), a division of Capital Group established in 1931 and headquartered in Los Angeles, California, is a powerhouse in active investment management, overseeing hundreds of billions in assets with a focus on global equity portfolios. Known for its long-term, research-intensive approach, CRGI employs a unique multiple-portfolio-manager system to diversify risk and enhance returns, serving institutional clients, financial advisors, and individual investors through vehicles like the American Funds mutual fund family. The firm’s investment philosophy emphasizes fundamental analysis and a deep understanding of companies worldwide, aiming to identify growth opportunities over extended horizons. As part of Capital Group’s broader mission, CRGI has built a reputation for delivering consistent, value-driven results in the global investment landscape.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$4.67B |
| 2 |
Chevron
CVX
|
+$1.05B |
| 3 |
Qualcomm
QCOM
|
+$762M |
| 4 |
American International
AIG
|
+$738M |
| 5 |
Freeport-McMoran
FCX
|
+$549M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MON
Monsanto Co
MON
|
+$1.64B |
| 2 |
STJ
St Jude Medical
STJ
|
+$1.43B |
| 3 |
Baidu
BIDU
|
+$1.32B |
| 4 |
Amgen
AMGN
|
+$995M |
| 5 |
General Dynamics
GD
|
+$677M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.37% |
| 2 | Technology | 11.56% |
| 3 | Communication Services | 10.85% |
| 4 | Consumer Staples | 10.33% |
| 5 | Industrials | 10.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
201
Truist Financial
TFC
$65B
| $236M | 0.08% |
6,615,000
-1,046,000
| -14% | -$36.6M |
|
202
Ultragenyx Pharmaceutical
RARE
$2.61B
| $234M | 0.08% |
4,778,169
+11,696
| +0.2% | +$757K |
|
203
TE Connectivity
TEL
$62.5B
| $232M | 0.08% |
4,068,461
-2,939,888
| -42% | -$177M |
|
204
CME Group
CME
$95.1B
| $231M | 0.08% |
2,370,428
-356,572
| -13% | -$33.7M |
|
205
Capital One
COF
$137B
| $229M | 0.08% |
3,610,101
+410,101
| +13% | +$28.6M |
|
206
Myriad Genetics
MYGN
$310M
| $229M | 0.08% |
7,482,135
-1,138,704
| -13% | -$39.6M |
|
207
Ralph Lauren
RL
$23.2B
| $229M | 0.08% |
2,550,003
+400,003
| +19% | +$37.2M |
|
|
FNSR
208
DELISTED
Finisar Corp
FNSR
| $224M | 0.08% |
12,815,280
+1,086,000
| +9% | +$18.6M |
|
209
Omnicom Group
OMC
$23.8B
| $221M | 0.08% |
2,706,334
+106,334
| +4% | +$8.84M |
|
210
D.R. Horton
DHI
$41.6B
| $210M | 0.07% |
6,685,000
| – | – |
|
211
Generac Holdings
GNRC
$13.2B
| $205M | 0.07% |
5,877,869
-279,557
| -5% | -$10.3M |
|
212
Markel Group
MKL
$22.9B
| $203M | 0.07% |
212,852
| – | – |
|
|
AVP
213
DELISTED
Avon Products, Inc.
AVP
| $202M | 0.07% |
53,360,808
+105,467
| +0.2% | +$454K |
|
214
Essent Group
ESNT
$6.17B
| $198M | 0.07% |
9,072,989
+1,180,000
| +15% | +$24.6M |
|
|
TMH
215
DELISTED
Team Health Holdings Inc
TMH
| $197M | 0.07% |
4,854,274
+4
| +0% | +$174 |
|
|
FDC
216
DELISTED
First Data Corporation
FDC
| $196M | 0.07% |
17,736,768
+11,613,227
| +190% | +$139M |
|
217
Oshkosh
OSK
$9.54B
| $196M | 0.07% |
4,107,223
-2,128,377
| -34% | -$94.4M |
|
|
BLUE
218
DELISTED
bluebird bio
BLUE
| $196M | 0.07% |
349,225
+302
| +0.1% | +$171K |
|
219
SM Energy
SM
$7.52B
| $195M | 0.07% |
7,208,940
+304,076
| +4% | +$8.53M |
|
|
STJ
220
DELISTED
St Jude Medical
STJ
| $187M | 0.06% |
2,396,930
-19,989,217
| -89% | -$1.43B |
|
221
Novartis
NVS
$290B
| $186M | 0.06% |
2,520,486
| – | – |
|
222
TJX Companies
TJX
$169B
| $186M | 0.06% |
4,815,484
+15,484
| +0.3% | +$591K |
|
|
CRZO
223
DELISTED
Carrizo Oil & Gas Inc
CRZO
| $186M | 0.06% |
5,176,973
+1,242,353
| +32% | +$44.4M |
|
224
JB Hunt Transport Services
JBHT
$26.4B
| $185M | 0.06% |
2,283,703
+228,184
| +11% | +$18.8M |
|
|
KMI.PRA
225
DELISTED
Kinder Morgan, Inc.
KMI.PRA
| $179M | 0.06% |
3,655,574
-1,229,351
| -25% | -$56.2M |
|
Similar funds
Capital Research Global Investors's Q2 2016 Portfolio in Review
As of Q2 2016, Capital Research Global Investors held 447 positions worth $292B, up 0.83% from $290B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Capital Research Global Investors's Q2 2016 filing shows 16 new, 145 increased, 141 reduced and 28 closed positions. Its largest new stake was Qualcomm: 14,466,460 shares worth $775M. The largest sale was Monsanto Co, an estimated $1.64B.
By sector, the portfolio is most concentrated in Healthcare at 19% of assets, up from 18% a quarter earlier, followed by Technology and Communication Services.
- Capital Research Global Investors's largest Q2 2016 buy was Qualcomm: 14,466,460 shares worth $775M.
- Capital Research Global Investors added most to AbbVie in Q2 2016, an estimated $4.67B increase.
- Capital Research Global Investors's biggest Q2 2016 reduction was Monsanto Co, cutting an estimated $1.64B.
- Capital Research Global Investors fully exited Cognizant in Q2 2016, selling an estimated $485M.
- Capital Research Global Investors's ten largest holdings make up 25% of its $292B portfolio in Q2 2016.
- Capital Research Global Investors opened 16 new positions and closed 28 in Q2 2016.
- Capital Research Global Investors's portfolio value rose 0.83% quarter-over-quarter to $292B.
Based on Capital Research Global Investors's 13F filing for Q2 2016, filed 15 Aug 2016.